History and Epidemiology | p. 1 |
History of Ductal Carcinoma in Situ | p. 3 |
Why Study Ductal Carcinoma in Situ | p. 12 |
The Natural History of Ductal Carcinoma in Situ of the Breast | p. 17 |
The Epidemiology of Breast Carcinoma in Situ | p. 22 |
Carcinogenesis and Biology | p. 35 |
Biologic Characteristics of Ductal Carcinoma in Situ | p. 37 |
Prognostic Factors in Ductal Carcinoma in Situ | p. 49 |
HER-2/neu Gene Amplification and Overexpression in Ductal Carcinoma in Situ | p. 54 |
New Insights into the Pathogenesis of in Situ Carcinomas of the Breast by Means of Comparative Genomic Hybridization (CGH) | p. 67 |
Model Systems for Ductal Carcinoma in Situ | p. 77 |
Detection and Evaluation | p. 85 |
Mammographic Appearances of in Situ Carcinomas | p. 87 |
Ductal Carcinoma in Situ: A Radiological Perspective | p. 105 |
Roles of Breast Magnetic Resonance Imaging for Ductal Carcinoma in Situ | p. 118 |
Ultrasound of Ductal Carcinoma in Situ | p. 128 |
Biopsy Techniques | p. 171 |
Minimally Invasive Biopsy | p. 173 |
Breast Biopsy and Oncoplastic Surgery for the Patient with Ductal Carcinoma in Situ: Surgical, Pathologic, and Radiologic Issues | p. 185 |
Pathology | p. 205 |
Practical Pathology of Duct Carcinoma in Situ: How to Derive Optimal Data from the Pathologic Examination | p. 207 |
The Van Nuys Ductal Carcinoma in Situ Classification: An Update | p. 222 |
Angiogenesis in Ductal Carcinoma in Situ of the Breast | p. 234 |
The Local Distribution of Ductal Carcinoma in Situ of the Breast: Whole-Organ Studies | p. 240 |
Large-Section (Macrosection) Histologic Slides | p. 249 |
Predicting Local Recurrence in Patients with Ductal Carcinoma in Situ | p. 255 |
The Diagnostic Reproducibility of Ductal Carcinoma in Situ | p. 264 |
Treatment of Ductal Carcinoma in Situ | p. 273 |
Surgical Overview of the Treatment of Ductal Carcinoma in Situ | p. 275 |
Overview of Conservative Surgery and Radiation Therapy Ductal Carcinoma in Situ | p. 287 |
The Lagios Experience | p. 303 |
Treatment of Subclinical Ductal Carcinoma in Situ of the Breast by Local Excision and Surveillance: An Updated Personal Experience | p. 308 |
Ductal Carcinoma in Situ: Experience at Nottingham City Hospital 1973 through 2000 | p. 322 |
Ductal Carcinoma in Situ: The Memorial Sloan-Kettering Cancer Center Experience | p. 329 |
The Van Nuys/USC Experience by Treatment | p. 337 |
Ductal Carcinoma in Situ: The Edinburgh Experience | p. 343 |
The Florence Experience | p. 348 |
Bayreuth-Erlangen Experience of "Risk-Adapted" Therapy of Ductal Carcinoma in Situ | p. 354 |
An International Collaborative Study: A 15-Year Experience | p. 359 |
Breast-Conserving Surgery Plus Radiation Therapy in Ductal Carcinoma in Situ: The Institut Curie Experience | p. 367 |
Joint Center for Radiation Therapy Experience | p. 373 |
The Impact of Young Age on Outcome in Patients with Ductal Carcinoma in Situ: The William Beaumont Hospital Experience | p. 381 |
Breast Conserving Therapy for Ductal Carcinoma in Situ: The Van Nuys Experience with Excision Plus Radiation Therapy | p. 394 |
Ductal Carcinoma in Situ: Collected Experience of the French Regional Comprehensive Cancer Centers | p. 400 |
Should All Ductal Carcinoma in Situ Patients Receive Radiation Therapy and Is Partial Breast Irradiation an Option? | p. 407 |
Randomized Trial Overview | p. 414 |
Prospective Clinical Trials: The National Surgical Adjuvant Breast Project Experience | p. 420 |
Prevention of Invasive Breast Cancer in Women with Ductal Carcinoma in Situ: An Update of the National Surgical Adjuvant Breast and Bowel Project Experience | p. 432 |
An Update on European Organization for Research and Treatment of Cancer Trial 10853 for Ductal Carcinoma in Situ of the Breast | p. 447 |
Radiotherapy and Tamoxifen after Complete Excision of Ductal Carcinoma in Situ of the Breast | p. 453 |
Tools for Selecting Patients for Breast Conservation with and without Radiation Therapy | p. 457 |
The University of Southern California/Van Nuys Prognostic Index | p. 459 |
Problems with the Use of the Van Nuys Prognostic Index | p. 474 |
Margin Width as the Sole Predictor of Local Recurrence in Patients with Ductal Carcinoma in Situ of the Breast | p. 482 |
Adjuvant Therapy, Prevention, and Hormone Replacement Therapy | p. 495 |
Can the New Prevention Strategies Reduce the Incidence of Ductal Carcinoma in Situ? | p. 497 |
Tamoxifen and/or Hormone Replacement Therapy after Treatment for Ductal Carcinoma in Situ | p. 502 |
Tamoxifen Chemoprevention for Ductal Carcinoma in Situ: Magic Bullet or Misstep? | p. 508 |
Other Issues | p. 513 |
Mastectomy and Immediate Reconstruction for Extensive Ductal Carcinoma in Situ of the Breast | p. 515 |
Ductal Carcinoma in Situ with Microinvasion | p. 523 |
Management of the Contralateral Breast | p. 530 |
Extensive Intraductal Component in Association with Invasive Breast Cancers | p. 536 |
Salvage of Local-Regional Failure | p. 539 |
Outcome after Invasive Local Recurrence in Patients with Ductal Carcinoma in Situ of the Breast | p. 545 |
Axillary Dissection for Ductal Carcinoma in Situ | p. 554 |
The Role of Sentinel Lymph Node Biopsy in Ductal Carcinoma in Situ: The Memorial Sloan-Kettering Opinion | p. 565 |
Explaining Ductal Carcinoma in Situ to Patients: The Role of Specific Information and Absolute Risks | p. 571 |
Ductal Carcinoma in Situ of the Male Breast | p. 577 |
Interstitial Therapy of Ductal Carcinoma in Situ: Where Does It Stand? | p. 581 |
The Ductal Carcinoma in Situ Consensus Conferences | p. 585 |
The European Organization for Research and Treatment of Cancer Ductal Carcinoma in Situ Consensus Meetings | p. 587 |
The Classification and Treatment of Ductal Carcinoma in Situ of the Breast: Summary of the 1997 and 1999 Consensus Conferences | p. 594 |
Other Noninvasive Breast Cancers and Preneoplastic Diseases | p. 601 |
Breast-Conserving Treatment of Paget's Disease of the Breast with Radiotherapy | p. 603 |
Paget's Disease | p. 607 |
Lobular Carcinoma in Situ | p. 615 |
Pathology of Ductal Carcinoma in Situ: Proliferative and Nonproliferative Benign Breast Disease | p. 635 |
Conclusion | p. 641 |
Editors' Consensus | p. 643 |
Index | p. 651 |
Table of Contents provided by Blackwell. All Rights Reserved. |